Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study - Wikidata - awgldk - TriplyDB

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

http://www.wikidata.org/entity/Q34343069

about

Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis Anticoagulation in atrial fibrillation Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.Data Resource Profile: The Danish National Prescription Registry.Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study).Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden.New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials.Enhanced elimination of dabigatran through extracorporeal methods.Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No.Developing alerting thresholds for prospective drug safety monitoring.Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making.National Trends in Ambulatory Oral Anticoagulant Use.Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database.Natural history of bleeding and characteristics of early bleeders among warfarin initiators - a cohort study in Finland.Engaging with quality improvement in anticoagulation management.Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort stu Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.Risk of Gastrointestinal Bleeding Among Dabigatran Users - A Self Controlled Case Series Analysis.Novel oral anticoagulants for stroke prevention in the geriatric population.Trends in oral anticoagulant use in Qatar: a 5-year experience.Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use.Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?Direct oral anticoagulants: unique properties and practical approaches to management.Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.Review And Insights Into The Bleeding Mechanism Incited By Antithrombotic Therapy: Mechanistic Nuances Of Dual Pro-Hemorrhagic Substrate Incorporating Drug-Induced Microvascular Leakage.Prevalence of drug-related problems associated with direct oral anticoagulants in hospitalized patients: a multicenter, cross-sectional study.

P2860

Q28085676-94D0293E-6613-4B19-A1CE-2439E4A9A25C Q28315636-5B49FBA8-88FF-44D8-B141-463E04F592F0 Q31098679-5CDC48B5-9C95-46B7-9714-E1014B74ACC8 Q31139554-1E4A2474-0EAB-45DE-B2D3-DD20959FD551 Q33552917-C503DDCE-4FCD-4534-869C-9411CBDF2C48 Q33854667-7A9B8B94-4E68-4C52-806D-0D3BA3617AE2 Q34109813-D48116DC-5CFA-498A-9016-678257C668C4 Q34571082-9049C744-ADB9-42BB-8552-CE69B925F149 Q34571099-995952B0-9F51-4DC0-97DF-61ABBD6178F7 Q34670808-8615E8B0-6A01-4E6D-8FC7-CC5D26F23D87 Q34694471-6D739903-A487-4414-B870-235D3A9D3574 Q35160888-50F063A3-D70A-4E65-A778-873D11E30837 Q35210137-39A96442-9173-40F1-92A2-A0595E3A1841 Q35550900-5AF1419F-72B4-442B-B126-83B7D3DFE5E0 Q35689817-38A8FDCB-7502-4FA9-A469-A1B52C4A69DF Q35848816-68078D47-ACF7-4178-B663-CB73B59F97B3 Q35883245-6682D9E8-20EA-4970-85DC-B5B96E8349A0 Q36113146-362DFA82-509B-4293-9DCE-CD856D9926BE Q36132510-2704BA05-FBAC-4783-850B-2CDD9415A661 Q36315659-0B82196B-06C5-4899-83E0-A5BFC8BD64AB Q36526677-694BB7FD-528F-4B43-9BF1-7201FE63F9DC Q36575256-36E2D4FC-5BFE-451A-B105-38BDE300834F Q36771378-21E2A207-E7A8-4CE3-A7E6-CC17BE1B05C4 Q36947797-3F7D2C0B-FF52-4E7E-AD40-5858967A997F Q37115524-5E472F29-37F5-45E0-BE6F-062758C50353 Q37226300-F1767625-7271-4C85-9B5B-6E61752520B4 Q37457554-CDF63AD3-C418-4DD9-AB7F-E03C4673625D Q37595293-14EE0D9E-3780-4B78-97E6-5D66115360DA Q38162796-FC3C54BE-7F10-4F82-AC8A-54DDD82D30E0 Q38403042-C90F8BE3-4044-4543-BC63-242B20838BFF Q38458642-92E514BE-E3B2-46F0-A281-E90229AD4A5F Q38664920-33CF1BF0-5D28-48B3-B756-7646A98D426C Q38712843-86D5BA2F-BD19-41A8-A3F2-EF7B92BFFEF5 Q38728028-8C319EC4-3D11-4EAD-8BC2-5B48B76927A6 Q38799019-91DD86E0-68C5-45D8-A736-ED67BC0E8EC7 Q38893463-9076E32A-78A0-451D-8C7E-F8254575773D Q38961671-0C84EAB3-374F-4068-92BE-F9B3182EDFF8 Q39023182-7D0F93FB-A3A7-4352-AD57-B307BA65B056 Q39037122-FF038B6A-900F-43D7-9994-31270148E08B Q39251933-312E2A0C-AFDC-47F3-82F2-7F43035CF0A8

P2860

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

http://www.wikidata.org/entity/Q34343069

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@ast

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@en

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@nl

type

label

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@ast

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@en

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@nl

prefLabel

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@ast

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@en

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@nl

P1433

Q34343069-B6D087EA-BD6E-4EEE-B508-3C597019CAE2

P1476

Q34343069-EB2A50BD-BD5E-4BCF-8B9E-0725251A2BF9

P2093

Q34343069-31E6EDFF-9D56-4DF1-8B6A-602B3D1FE377

Q34343069-4740C437-65A6-40F6-9B8F-34374691DE6F

Q34343069-5148B6E9-2C92-4E72-80C6-36FECC5C4F97

Q34343069-7C1374FA-D401-477F-8685-F66F5ED030B5

Q34343069-8BD7778C-5BC6-4FBE-A359-66268A111259

Q34343069-901B5F81-A08A-4DFD-B5BE-A6ECB8C1E78C

Q34343069-9095276F-E20F-4723-9CDC-CA94CBB7B459

Q34343069-A6397455-4F53-4F51-BE62-676C961834B3

P2860

Q34343069-002281B6-7614-4BA0-9CF5-F3EA39842C3F

Q34343069-0947E20C-3B6C-43B7-9E7E-86142E67D7CA

Q34343069-0F31E490-D917-4633-8E46-3918EB5DA9DA

Q34343069-1C8B400E-842F-48B7-BF95-DC149E677BA2

Q34343069-218B24B9-4A88-48C8-AC32-ABACF7011C67

Q34343069-2367DAA7-DB76-4636-B65E-C297F63D493E

Q34343069-24C820C8-9DA5-41F9-942D-5E6D1FD44B39

Q34343069-290D003B-ED81-4F38-A084-02E6802C5A8D

Q34343069-2C2541FE-3724-4A22-A6E4-A97B8FBED75D

Q34343069-3117E6C7-5C13-4B0C-9A68-7A1C6002BE17

P31

Q34343069-79BF3A12-1F85-47E0-A346-CEA2E2BB3217

P356

Q34343069-2BE96149-028E-4EBA-9784-3B491163D42F

P433

Q34343069-ECB7B485-1BA5-4C4E-9E40-2AAD44A68032

P478

Q34343069-3B990DD5-8CDA-4DB6-8399-DFF96B4340C5

P50

Q34343069-1BD254AC-DD84-40F9-9135-108C885C68A5

Q34343069-819E56B3-94A9-4A41-9849-1D6728031FA2

Q34343069-9A223777-4571-498E-8785-6C9164ACA17B

Q34343069-9E2245B7-4216-4505-B31D-B3511202FB08

Q34343069-D1539580-52FC-46A5-A15C-F1F076E6EEAF

P577

Q34343069-DA7B2108-A6AD-4750-9DB1-12B0CEE82242

P5875

Q34343069-FD9CE444-8B11-48B2-B6DA-F53FEDF317E1

P698

Q34343069-25924BA1-234B-417E-A6ED-1A7FC508878C

P921

Q34343069-1C63F6F5-4EC4-4114-891F-81D1A062D3A5

P932

Q34343069-9DA0C007-2D48-49B2-8F3B-F9EE55E46077

P356

BMJOPEN-2013-002758

P1433

P1476

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

@en

P2093

Deniz Karasoy

http://www.w3.org/2001/XMLSchema#string

Emil L Fosbøl

http://www.w3.org/2001/XMLSchema#string

Mette Charlot

http://www.w3.org/2001/XMLSchema#string

Morten Lamberts

http://www.w3.org/2001/XMLSchema#string

Morten Lock Hansen

http://www.w3.org/2001/XMLSchema#string

Morten W Hvidtfeldt

http://www.w3.org/2001/XMLSchema#string

Peter Weeke

http://www.w3.org/2001/XMLSchema#string

Rikke Sørensen

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Dabigatran versus warfarin in patients with atrial fibrillation

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Apixaban versus warfarin in patients with atrial fibrillation

[Data validity and coverage in the Danish National Health Registry. A literature review]

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.

Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data.

P31

scholarly article

P356

10.1136/BMJOPEN-2013-002758

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Christian Torp-Pedersen

Gunnar Hilmar Gislason

Gregory Y. H. Lip

Jonas Bjerring Olesen

P577

2013-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236639813

http://www.w3.org/2001/XMLSchema#string

P698

23645926

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

3646187

http://www.w3.org/2001/XMLSchema#string